Asymptomatic carriers of presenilin-1 E318G variant show no cerebrospinal fluid biochemical signs suggestive of Alzheimer's disease in a family with late-onset dementia

Vladimiro Artuso, Luisa Benussi, Roberta Ghidoni, Soraya Moradi-Bachiller, Federica Fusco, Stefano Curtolo, Ignazio Roiter, Gianluigi Forloni, Diego Albani

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Presenilin-1 (PSEN-1) is a component of the g-secretase complex involved in b-amyloid precursor protein (AbPP) processing. Usually Alzheimer's disease (AD)-linked mutations in the PSEN-1 gene lead to early onset and increase the production of the aggregation-prone peptide Ab42. However, the PSEN-1 E318G variant has an unclear pathogenic role, and was recently reported as a genetic risk factor for AD. In particular, E318G variant presence correlated with increased cerebrospinal fluid (CSF) levels of total tau (t-tau) and phosphorylated tau (p-tau).

OBJECTIVE: We describe a large Italian family, which we followed from January 2003 to January 2018, with late-onset AD and the E318G variant, with the aim of assessing E318G-associated CSF or plasma biochemical changes in biomarkers of dementia.

METHOD: CSF Ab42, t-tau and p-tau, plasma Ab42 and Ab40 were assessed by ELISA tests, while CSF amyloid peptides profile was investigated by mass spectrometry.

RESULTS: We did not find any changes in CSF biochemical markers (Ab42, t-tau, p-tau and amyloid peptides) of asymptomatic E318G carriers in 2010 and 2012, but plasma Ab40 was increased at the same times. From 2003 to 2018, no asymptomatic E318G carrier developed AD.

CONCLUSION: Our follow-up of this family may help elucidate E318G's role in AD and globally points to a null effect of this variant.

Original languageEnglish
JournalCurrent Alzheimer Research
DOIs
Publication statusE-pub ahead of print - Oct 31 2018

Fingerprint

Presenilin-1
Cerebrospinal Fluid
Dementia
Alzheimer Disease
Amyloid
Peptides
Biomarkers
Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
Mass Spectrometry
Enzyme-Linked Immunosorbent Assay
Mutation
Genes

Cite this

Asymptomatic carriers of presenilin-1 E318G variant show no cerebrospinal fluid biochemical signs suggestive of Alzheimer's disease in a family with late-onset dementia. / Artuso, Vladimiro; Benussi, Luisa; Ghidoni, Roberta; Moradi-Bachiller, Soraya; Fusco, Federica; Curtolo, Stefano; Roiter, Ignazio; Forloni, Gianluigi; Albani, Diego.

In: Current Alzheimer Research, 31.10.2018.

Research output: Contribution to journalArticle

@article{904d36a4b3be4b0983a655328eac2009,
title = "Asymptomatic carriers of presenilin-1 E318G variant show no cerebrospinal fluid biochemical signs suggestive of Alzheimer's disease in a family with late-onset dementia",
abstract = "BACKGROUND: Presenilin-1 (PSEN-1) is a component of the g-secretase complex involved in b-amyloid precursor protein (AbPP) processing. Usually Alzheimer's disease (AD)-linked mutations in the PSEN-1 gene lead to early onset and increase the production of the aggregation-prone peptide Ab42. However, the PSEN-1 E318G variant has an unclear pathogenic role, and was recently reported as a genetic risk factor for AD. In particular, E318G variant presence correlated with increased cerebrospinal fluid (CSF) levels of total tau (t-tau) and phosphorylated tau (p-tau).OBJECTIVE: We describe a large Italian family, which we followed from January 2003 to January 2018, with late-onset AD and the E318G variant, with the aim of assessing E318G-associated CSF or plasma biochemical changes in biomarkers of dementia.METHOD: CSF Ab42, t-tau and p-tau, plasma Ab42 and Ab40 were assessed by ELISA tests, while CSF amyloid peptides profile was investigated by mass spectrometry.RESULTS: We did not find any changes in CSF biochemical markers (Ab42, t-tau, p-tau and amyloid peptides) of asymptomatic E318G carriers in 2010 and 2012, but plasma Ab40 was increased at the same times. From 2003 to 2018, no asymptomatic E318G carrier developed AD.CONCLUSION: Our follow-up of this family may help elucidate E318G's role in AD and globally points to a null effect of this variant.",
author = "Vladimiro Artuso and Luisa Benussi and Roberta Ghidoni and Soraya Moradi-Bachiller and Federica Fusco and Stefano Curtolo and Ignazio Roiter and Gianluigi Forloni and Diego Albani",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
month = "10",
day = "31",
doi = "10.2174/1567205015666181031150345",
language = "English",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Asymptomatic carriers of presenilin-1 E318G variant show no cerebrospinal fluid biochemical signs suggestive of Alzheimer's disease in a family with late-onset dementia

AU - Artuso, Vladimiro

AU - Benussi, Luisa

AU - Ghidoni, Roberta

AU - Moradi-Bachiller, Soraya

AU - Fusco, Federica

AU - Curtolo, Stefano

AU - Roiter, Ignazio

AU - Forloni, Gianluigi

AU - Albani, Diego

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018/10/31

Y1 - 2018/10/31

N2 - BACKGROUND: Presenilin-1 (PSEN-1) is a component of the g-secretase complex involved in b-amyloid precursor protein (AbPP) processing. Usually Alzheimer's disease (AD)-linked mutations in the PSEN-1 gene lead to early onset and increase the production of the aggregation-prone peptide Ab42. However, the PSEN-1 E318G variant has an unclear pathogenic role, and was recently reported as a genetic risk factor for AD. In particular, E318G variant presence correlated with increased cerebrospinal fluid (CSF) levels of total tau (t-tau) and phosphorylated tau (p-tau).OBJECTIVE: We describe a large Italian family, which we followed from January 2003 to January 2018, with late-onset AD and the E318G variant, with the aim of assessing E318G-associated CSF or plasma biochemical changes in biomarkers of dementia.METHOD: CSF Ab42, t-tau and p-tau, plasma Ab42 and Ab40 were assessed by ELISA tests, while CSF amyloid peptides profile was investigated by mass spectrometry.RESULTS: We did not find any changes in CSF biochemical markers (Ab42, t-tau, p-tau and amyloid peptides) of asymptomatic E318G carriers in 2010 and 2012, but plasma Ab40 was increased at the same times. From 2003 to 2018, no asymptomatic E318G carrier developed AD.CONCLUSION: Our follow-up of this family may help elucidate E318G's role in AD and globally points to a null effect of this variant.

AB - BACKGROUND: Presenilin-1 (PSEN-1) is a component of the g-secretase complex involved in b-amyloid precursor protein (AbPP) processing. Usually Alzheimer's disease (AD)-linked mutations in the PSEN-1 gene lead to early onset and increase the production of the aggregation-prone peptide Ab42. However, the PSEN-1 E318G variant has an unclear pathogenic role, and was recently reported as a genetic risk factor for AD. In particular, E318G variant presence correlated with increased cerebrospinal fluid (CSF) levels of total tau (t-tau) and phosphorylated tau (p-tau).OBJECTIVE: We describe a large Italian family, which we followed from January 2003 to January 2018, with late-onset AD and the E318G variant, with the aim of assessing E318G-associated CSF or plasma biochemical changes in biomarkers of dementia.METHOD: CSF Ab42, t-tau and p-tau, plasma Ab42 and Ab40 were assessed by ELISA tests, while CSF amyloid peptides profile was investigated by mass spectrometry.RESULTS: We did not find any changes in CSF biochemical markers (Ab42, t-tau, p-tau and amyloid peptides) of asymptomatic E318G carriers in 2010 and 2012, but plasma Ab40 was increased at the same times. From 2003 to 2018, no asymptomatic E318G carrier developed AD.CONCLUSION: Our follow-up of this family may help elucidate E318G's role in AD and globally points to a null effect of this variant.

U2 - 10.2174/1567205015666181031150345

DO - 10.2174/1567205015666181031150345

M3 - Article

C2 - 30381075

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

ER -